Outcome
    Strong Evidence

    Magnesium for Headache Relief

    Magnesium is a guideline-supported migraine preventive, with the strongest evidence for menstrual migraine and deficiency states.

    Overview

    Magnesium is one of the few supplements with a genuine place in headache guidelines. The American Headache Society and American Academy of Neurology rate it as probably effective for migraine prevention, and the American Migraine Foundation suggests 400-500 mg of elemental magnesium daily. Trials report reductions in migraine frequency of around 40% in responders over 8 to 12 weeks. It is prevention rather than rescue. Magnesium does not reliably abort a headache in progress; it reduces how often they arrive. People with low serum or intracellular magnesium, menstrual migraine, or migraine with aura appear to respond best, which fits a deficiency-correction model more than a pharmacological one.

    Verdict

    Strong yes

    Guideline-endorsed as probably effective for migraine prevention at 400-600 mg elemental daily. Effects build over 8-12 weeks and are largest in menstrual migraine and migraine with aura; it is not an acute treatment.

    How It Works

    Magnesium blocks the NMDA receptor's ion channel in a voltage-dependent way. Low magnesium removes that block, increasing glutamatergic excitability and lowering the threshold for cortical spreading depression — the wave of neuronal depolarisation that underlies migraine aura and is thought to trigger the headache phase. Several supporting actions point the same direction. Magnesium is a physiological calcium antagonist, promoting cerebral vasodilation and opposing vasospasm; it modulates serotonin receptor activity and substance P release in the trigeminovascular system; and it reduces platelet aggregation. Studies consistently find lower brain and serum magnesium in people with migraine than in controls, which is the strongest circumstantial argument for repletion.

    Pathways involved

    NMDA receptor voltage-dependent block
    Cortical spreading depression threshold
    Calcium channel antagonism
    Cerebral vascular tone
    Serotonin receptor modulation
    Trigeminovascular substance P release

    Dosing & Protocol

    ScenarioDoseFormTiming
    Migraine prevention (guideline)400-600 mg elemental dailyMagnesium citrate or glycinateSplit into 2 doses with food
    Starting dose200 mg elemental dailyCitrate or glycinateEvening with food
    Loose-stool-prone users300-400 mg elemental dailyGlycinate or malateSplit doses
    Menstrual migraine400-600 mg elemental dailyCitrateContinuous, or from day 15 of cycle
    1. 1

      Choose an absorbable form· Before starting

      Citrate, glycinate and malate absorb well. Magnesium oxide is cheap and poorly absorbed, and is mostly a laxative — though some trials did use it.

    2. 2

      Start at 200 mg and split doses· Week 1-2

      Splitting improves absorption and reduces the osmotic diarrhoea that is the dose-limiting effect.

    3. 3

      Build to 400-600 mg elemental daily· Weeks 2-4

      Increase gradually to the guideline range as the gut tolerates it.

    4. 4

      Keep a headache diary· Ongoing

      Track days per month, severity and rescue medication use from before you start. Migraine frequency is variable enough that memory is unreliable.

    5. 5

      Judge at 12 weeks· Week 12

      Prophylactic effects build slowly. Three months at an adequate dose is a fair trial before deciding it has failed.

    Elemental magnesium, not total salt weight

    A 500 mg magnesium citrate capsule may supply only about 80 mg of elemental magnesium. Guideline doses refer to the elemental figure, which is usually printed in smaller type on the label.

    Evidence

    Randomised placebo-controlled trials of oral magnesium for migraine prophylaxis have generally reported reductions in attack frequency of roughly 40% in treated groups at doses of 600 mg daily over 12 weeks, with additional evidence in menstrual migraine and in paediatric populations. On this basis American Headache Society and American Academy of Neurology guidelines classify magnesium as Level B, probably effective. The literature is not uniform: some trials are null, the magnesium salt and dose vary widely, and gastrointestinal effects make blinding imperfect. Intravenous magnesium in acute migraine is a separate question with mixed results, most favourable for attacks with aura. No individual trials are linked to this pairing in our database yet, so this reflects the wider literature rather than pair-specific citations.
    Best available evidence
    Randomised placebo-controlled prophylaxis trials; AHS/AAN Level B
    Typical effect
    Around 40% reduction in attack frequency in responders
    Studied dose
    400-600 mg elemental daily, split
    Time to effect
    8-12 weeks
    Certainty of evidence
    Moderate

    Safety

    Kidney function sets the ceiling

    Magnesium is cleared renally. In chronic kidney disease, supplementation can cause hypermagnesaemia — weakness, low blood pressure, cardiac conduction problems. Do not take prophylactic doses without medical advice if kidney function is impaired.

    Common effects

    Loose stools and diarrhoea (dose-limiting)
    Abdominal cramping
    Nausea
    Hypermagnesaemia in renal impairment
    Interference with several drug absorptions

    Interactions & Conflicts

    Interacts withSeverityMechanismAction
    Tetracycline and quinolone antibiotics
    moderate
    		Chelation reduces antibiotic absorptionSeparate by at least 2 hours before or 4-6 hours after
    Bisphosphonates
    moderate
    		Reduced drug absorptionSeparate by at least 2 hours
    Levothyroxine
    moderate
    		Impaired thyroxine absorptionSeparate by 4 hours
    Proton pump inhibitors
    low
    		Long-term PPI use lowers magnesium; combined effects on levels are unpredictableMonitor magnesium on long-term PPI therapy
    Potassium-sparing diuretics
    moderate
    		Reduced renal magnesium excretionMonitor levels; clinician review

    References

    1. Peikert A et al. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996
    2. Holland S et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.